Tauklarify imaging shows tau tangles in the living brain for adults with thinking problems evaluated for Alzheimer's. For younger-onset families, the key questions are what positive and negative results mean and what step comes next.
Tauklarify is florquinitau F 18 injection, a radioactive tracer that sticks to clumped tau. The FDA approved it on Aug. 14, 2026 for brain PET in cognitively impaired adults evaluated for Alzheimer's, according to the Pharmacy Times approval report.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does Tauklarify actually detect?
- What does a positive or negative result mean?
- Why does younger onset change the reading?
- What should families ask before and after the scan?
- Frequently Asked Questions
What does Tauklarify actually detect?
Tauklarify is a tau PET tracer. It binds aggregated tau and lights up neurofibrillary tangles during a brain scan. Those tangles are a core Alzheimer's injury, along with amyloid plaques. It can show tangles even when they sit only in the medial temporal lobe.
That area handles memory and is often affected first. Tauklarify is the second FDA-approved tau PET tracer after Tauvid, according to the Biospace announcement from Enigma Biomedical USA. The scan does not measure memory itself. It maps where tau has built up so a clinician can match biology to symptoms.
What does a positive or negative result mean?
A positive scan means the reader saw an Alzheimer's-like tau pattern. A negative scan means that pattern was not seen. Neither result alone makes the diagnosis. In two studies with 617 scans read by five blinded readers, negative agreement was 93%-99% and positive agreement was 68%-88%.
Interreader agreement was strong, with Fleiss kappa near 0.86-0.92, according to the NeurologyLive approval summary. FDA labeling warns that a negative scan does not rule out tau pathology. A positive scan does not by itself prove Alzheimer's disease under the microscope. Validation mainly compared unimpaired amyloid-negative people with impaired amyloid-positive patients, so accuracy may be lower at earlier stages.
Why does younger onset change the reading?
Younger-onset Alzheimer's means symptoms start before age 65, often in the 40s or 50s. It affects about 200,000 Americans who may still work, raise children, and manage benefits and income. Younger symptomatic patients often carry heavier, wider tau across outer brain areas. Parietal and frontoparietal hubs are common sites.
More widespread tau predicts faster tau spread and faster decline. That pattern can make a scan clearer when symptoms are present, but it also raises the stakes. A positive result in a working parent may affect job duties, driving, childcare plans, and treatment eligibility. The 2025 Alzheimer's Association-SNMMI criteria call amyloid and tau PET appropriate for MCI or dementia under 65 when Alzheimer's is suspected and the result will change diagnosis or treatment eligibility.
What should families ask before and after the scan?
Ask how the result will change care. Useful cases include sorting Alzheimer's from other causes, confirming eligibility for amyloid-directed treatment, or planning support at home and work.
Do not seek Tauklarify for suspected progressive supranuclear palsy, frontotemporal degeneration, or another non-Alzheimer tau disorder. Safety and effectiveness are not established there. Bring a full drug list, prior brain scans, and examples of daily problems to the follow-up visit.
- Will amyloid testing come first or with tau PET?
- Who will read the scan, and will a second reader check it?
- If the result is borderline, what repeat test or visit follows?
- How will work notes, driving, safety, and family care change after the result?
Frequently Asked Questions
Is Tauklarify better for early tangles than the older tracer?
A within-person Lancet comparison found MK-6240 spotted tangles earlier and separated Alzheimer's impairment better than Tauvid, with AUC 0.93 versus 0.86.
Can a person under 65 get this scan?
Yes, when there is MCI or dementia, Alzheimer's is suspected, and the result will affect diagnosis or treatment choice under appropriate-use criteria.
You Might Also Like
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: Result Interpretation Questions for Younger-Onset Alzheimer’s Families
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Result Interpretation Questions for Younger-Onset Alzheimer’s Families
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: Questions Family Caregivers Can Ask an Alzheimer’s Specialist
